BETHESDA, Md., Dec. 16, 2021 /PRNewswire/ -- The American
Medical Association (AMA), American Society of Anesthesiologists
(ASA), American Society of Health-System Pharmacists (ASHP),
Association for Clinical Oncology (ASCO), and the United States
Pharmacopeia (USP) today released a series of policy and
marketplace recommendations to address significant challenges in
our nation's drug supply chain that have been exacerbated by the
COVID-19 pandemic.
New recommendations address pharmaceutical supply access and
quality issues affecting the U.S. healthcare supply chain.
The report, "Improving the Quality and Resilience of the United
States Health Care Supply Chain," provides solutions to the
country's long-standing pharmaceutical supply access and quality
issues that threaten the resilience of our health care supply
chain.
The health care groups stated, "COVID-19 has magnified the
dangers inherent in failing to address gaps and deficiencies in the
pharmaceutical and medical supply chains. Supply chain disruptions
can adversely impact patient care by delaying treatment or
requiring patients to switch to less effective treatment regimens.
Policymakers must do more to ensure a consistently safe, effective,
and uninterrupted supply of quality medicines for patients in this
country."
The organizations have long collaborated on recommendations for
critical steps to improve our nation's supply chain and mitigate
drug shortages, including a summit in July
2020 that examined the resilience of the U.S. pharmaceutical
supply chain in light of the current state of global pharmaceutical
manufacturing. The group is asking policymakers to implement a
range of legislative and regulatory actions, including:
- Incentivize the development and use of advanced manufacturing
technology and develop new continuous manufacturing technology for
critical drugs and active pharmaceutical ingredients –
recommendations include adopting and implementing technologies in
domestic and foreign manufacturing facilities.
- Improve the function, composition, and accessibility of the
U.S. Strategic National Stockpile during public health
emergencies.
- Improve international cooperation and collaboration with
foreign supply chain partners, including but not limited to foreign
governments and manufacturers.
The full list of policy and marketplace recommendations can be
accessed here.
View original
content:https://www.prnewswire.com/news-releases/health-care-groups-release-drug-supply-chain-recommendations-301446556.html
SOURCE ASHP (American Society of Health-System Pharmacists)